Entrada Therapeutics (TRDA) Other Gross PP&E Adjustments: 2022-2025
Historic Other Gross PP&E Adjustments for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$43.5 million.
- Entrada Therapeutics' Other Gross PP&E Adjustments rose 20.13% to -$43.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$188.7 million, marking a year-over-year increase of 21.13%. This contributed to the annual value of -$53.2 million for FY2024, which is 19.52% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' Other Gross PP&E Adjustments is -$43.5 million, which was up 2.23% from -$44.5 million recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Other Gross PP&E Adjustments ranged from a high of -$1.0 million in Q1 2023 and a low of -$72.9 million during Q2 2023.
- Over the past 3 years, Entrada Therapeutics' median Other Gross PP&E Adjustments value was -$54.5 million (recorded in 2024), while the average stood at -$51.8 million.
- As far as peak fluctuations go, Entrada Therapeutics' Other Gross PP&E Adjustments surged by 95.48% in 2023, and later tumbled by 5,942.55% in 2024.
- Over the past 4 years, Entrada Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at -$15.5 million in 2022, then tumbled by 327.26% to -$66.1 million in 2023, then increased by 19.52% to -$53.2 million in 2024, then climbed by 20.13% to -$43.5 million in 2025.
- Its last three reported values are -$43.5 million in Q3 2025, -$44.5 million for Q2 2025, and -$47.4 million during Q1 2025.